Compare VENUS REMEDIES with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ALEMBIC - Comparison Results

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ALEMBIC VENUS REMEDIES/
ALEMBIC
 
P/E (TTM) x -15.9 65.2 - View Chart
P/BV x 1.1 5.6 18.9% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   ALEMBIC
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ALEMBIC
Mar-18
VENUS REMEDIES/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs12672 174.9%   
Low Rs6134 180.2%   
Sales per share (Unadj.) Rs301.84.7 6,420.3%  
Earnings per share (Unadj.) Rs-24.96.1 -407.5%  
Cash flow per share (Unadj.) Rs2.56.2 40.7%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs293.340.7 721.3%  
Shares outstanding (eoy) m12.34267.03 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.311.3 2.8%   
Avg P/E ratio x-3.88.7 -43.3%  
P/CF ratio (eoy) x36.78.5 433.4%  
Price / Book Value ratio x0.31.3 24.5%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m1,15414,139 8.2%   
No. of employees `0000.9NA-   
Total wages/salary Rs m393207 189.5%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,7241,255 296.7%  
Other income Rs m23370 6.1%   
Total revenues Rs m3,7471,625 230.5%   
Gross profit Rs m395111 355.4%  
Depreciation Rs m33838 895.0%   
Interest Rs m3542 20,841.2%   
Profit before tax Rs m-275442 -62.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3224 131.9%   
Profit after tax Rs m-3071,630 -18.8%  
Gross profit margin %10.68.9 119.8%  
Effective tax rate %-11.55.4 -211.7%   
Net profit margin %-8.2129.8 -6.3%  
BALANCE SHEET DATA
Current assets Rs m2,6381,867 141.3%   
Current liabilities Rs m2,305591 389.8%   
Net working cap to sales %8.9101.6 8.8%  
Current ratio x1.13.2 36.2%  
Inventory Days Days13594 143.7%  
Debtors Days Days4674 63.0%  
Net fixed assets Rs m4,8711,791 272.0%   
Share capital Rs m123534 23.1%   
"Free" reserves Rs m3,49610,324 33.9%   
Net worth Rs m3,61910,858 33.3%   
Long term debt Rs m1,37441 3,335.9%   
Total assets Rs m7,50911,591 64.8%  
Interest coverage x0.2260.9 0.1%   
Debt to equity ratio x0.40 10,008.1%  
Sales to assets ratio x0.50.1 458.0%   
Return on assets %0.614.1 4.5%  
Return on equity %-8.515.0 -56.5%  
Return on capital %1.615.2 10.4%  
Exports to sales %01.5 0.0%   
Imports to sales %13.921.0 66.1%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs m517263 196.1%   
Fx inflow Rs m019 0.0%   
Fx outflow Rs m517264 195.8%   
Net fx Rs m-517-244 211.3%   
CASH FLOW
From Operations Rs m514236 218.2%  
From Investments Rs m-123-224 55.0%  
From Financial Activity Rs m-387-27 1,455.3%  
Net Cashflow Rs m4-15 -28.4%  

Share Holding

Indian Promoters % 32.9 64.0 51.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.2 90.0%  
FIIs % 0.6 9.7 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 26.1 254.4%  
Shareholders   20,121 54,701 36.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Lower Oxygen Supplies to Affect 5 Sectors, Tata Steel's Blockchain Transaction, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a positive note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 375 points (up 0.8%).

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Apr 22, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS